You are here

J Surg Res DOI:10.1016/j.jss.2014.01.056

Selective inhibition of histone deacetylase 6 alters the composition of circulating blood cells in a lethal septic model.

Publication TypeJournal Article
Year of Publication2014
AuthorsZhao, T, Li, Y, Liu, B, Halaweish, I, Mazitschek, R, Alam, HB
JournalJ Surg Res
Volume190
Issue2
Pages647-54
Date Published2014 Aug
ISSN1095-8673
KeywordsAnimals, Disease Models, Animal, Hematocrit, Hemoglobins, Histone Deacetylase Inhibitors, Histone Deacetylases, Hydroxamic Acids, Indoles, Lymphocyte Count, Male, Mice, Mice, Inbred C57BL, Platelet Count, Random Allocation, Sepsis
Abstract

BACKGROUND: Phagocytes, especially monocytes, macrophages, and dendritic cells, play a pivotal role in the innate and adaptive immune responses during sepsis. We have shown that inhibition of histone deacetylase 6 improves survival and increases bacterial clearance in a mouse model of cecal ligation and puncture (CLP). The aim of this study was to determine whether this effect was associated with changes in the number and composition of different blood cell types in the circulation.

METHODS: C57BL/6J mice were subjected to CLP, and 1 h later given an intraperitoneal injection of either Tubastatin A dissolved in dimethyl sulfoxide, or dimethyl sulfoxide only. Sham-operated animals were treated in an identical fashion but not subjected to CLP. Forty-eight hours later, peripheral blood was obtained via cardiac puncture and analyzed using a HemaTrue veterinary hematology analyzer.

RESULTS: Tubastatin A administration increased the number of circulating monocytes in the sham-operated and the CLP animals. In comparison with the sham, CLP animals displayed an increase in the granulocyte percentage in white blood cells and decrease in the lymphocyte number and percentage, with a resultant increase in the granulocyte-to-lymphocyte ratio. Treatment of CLP animals with Tubastatin A decreased the granulocyte percentage and restored the lymphocyte number and percentage, which decreased the granulocyte-to-lymphocyte ratio. In the sham animals, Tubastatin A increased red blood cell number, hematocrit, and hemoglobin. This effect was not seen in CLP animals.

CONCLUSIONS: Tubastatin A treatment has significant impact on the composition of circulating blood cells. It increases the number of circulating monocytes and the red blood cell mass in sham-operated animals. In the CLP animals, it increases the monocyte count, decreases the percentage of granulocytes, restores the lymphocyte population, and decreases the granulocyte-to-lymphocyte ratio. These results may explain why Tubastatin A treatment improves survival in the septic models.

URLhttp://linkinghub.elsevier.com/retrieve/pii/S0022-4804(14)00102-4
DOI10.1016/j.jss.2014.01.056
Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/24613069?dopt=Abstract

Alternate JournalJ. Surg. Res.
PubMed ID24613069
PubMed Central IDPMC4267528
Grant ListP50 CA086355 / CA / NCI NIH HHS / United States
R01 GM084127 / GM / NIGMS NIH HHS / United States